Early research (Phase 1)Looking for participantsNCT05836896
What this trial is testing
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
Who this might be right for
NeoplasmsRelapsed Diffuse Large B-cell Lymphoma (DLBCL)Refractory Diffuse Large B-cell Lymphoma (DLBCL)+2 more
Technische Universität Dresden 16